Targeted Janus kinase inhibition versus adalimumab in psoriatic arthritis: evidence from a network meta-analysis

Objectives We conducted this network meta-analysis (NMA) to investigate the comparative effectiveness and safety of adalimumab, a tumor necrosis factor inhibitor (TNFi), and different oral Janus kinase inhibitors (JAKi) in psoriatic arthritis (PsA). Methods We systematically searched PubMed, Scopus, and Web of Science through November 2025 to identify studies evaluating JAKi and adalimumab in adults with active psoriatic arthritis. In R version 4.4.2, an NMA was performed using a random-effects model to obtain both pairwise and network effect estimates. Subsequently, treatments were ranked by their P-scores. Results A systematic literature search identified 6 included studies. All targeted therapies improved American College of Rheumatology (ACR) responses versus placebo, with risk ratios (RRs) for ACR20 ranging from 1.88 to 2.26 and for ACR50 from 2.50 to 4.74; upadacitinib 30 mg ranked highest across ACR20/50/70. All agents also increased minimal disease activity (MDA) (RRs 2.41–4.85) and 75% Improvement in Psoriasis Area and Severity Index (PASI75) responses (RRs 2.40–3.07) versus placebo. Patient-reported outcomes (HAQ-DI, FACIT-F, SF-36 PCS) improved with all treatments. Upadacitinib 30 mg was associated with higher risks of any infection (RR 1.36), serious infection (RR 3.32), and anaemia (RR 5.51) compared with placebo, and with slightly higher overall adverse events (AEs) than adalimumab. Conclusion Approved JAK inhibitor regimens and adalimumab appear to have broadly comparable short-term efficacy in PsA. Although upadacitinib 30 mg achieved higher efficacy estimates, it was associated with more adverse events and has limited direct clinical applicability. Treatment decisions should therefore weigh potential benefits against risks and safety considerations for each patient.

Authors

Institutions

Publication Details

Journal
Egyptian Rheumatology and Rehabilitation
Published
2026-11-19
DOI
https://doi.org/10.1186/s43166-026-00463-4
Primary Topic
Spondyloarthritis Studies and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Targeted Janus kinase inhibition versus adalimumab in psoriatic arthritis: evidence from a network meta-analysis

Abdulrahman M Hassan, Moaz M. Hassan, Abdulrahman Ali Alshehri, Mohamed Hassan Abbas Aly et al.
Egyptian Rheumatology and Rehabilitation
Spondyloarthritis Studies and Treatments
article

Targeted Janus kinase inhibition versus adalimumab in psoriatic arthritis: evidence from a network meta-analysis

Abdulrahman M Hassan, Moaz M. Hassan, Abdulrahman Ali Alshehri, Mohamed Hassan Abbas Aly, Alhanouf A Bakhashwain, Abdelghaffar Mohammed, Khaled R. Bonadugji
article en

Abstract

Objectives We conducted this network meta-analysis (NMA) to investigate the comparative effectiveness and safety of adalimumab, a tumor necrosis factor inhibitor (TNFi), and different oral Janus kinase inhibitors (JAKi) in psoriatic arthritis (PsA). Methods We systematically searched PubMed, Scopus, and Web of Science through November 2025 to identify studies evaluating JAKi and adalimumab in adults with active psoriatic arthritis. In R version 4.4.2, an NMA was performed using a random-effects model to obtain both pairwise and network effect estimates. Subsequently, treatments were ranked by their P-scores. Results A systematic literature search identified 6 included studies. All targeted therapies improved American College of Rheumatology (ACR) responses versus placebo, with risk ratios (RRs) for ACR20 ranging from 1.88 to 2.26 and for ACR50 from 2.50 to 4.74; upadacitinib 30 mg ranked highest across ACR20/50/70. All agents also increased minimal disease activity (MDA) (RRs 2.41–4.85) and 75% Improvement in Psoriasis Area and Severity Index (PASI75) responses (RRs 2.40–3.07) versus placebo. Patient-reported outcomes (HAQ-DI, FACIT-F, SF-36 PCS) improved with all treatments. Upadacitinib 30 mg was associated with higher risks of any infection (RR 1.36), serious infection (RR 3.32), and anaemia (RR 5.51) compared with placebo, and with slightly higher overall adverse events (AEs) than adalimumab. Conclusion Approved JAK inhibitor regimens and adalimumab appear to have broadly comparable short-term efficacy in PsA. Although upadacitinib 30 mg achieved higher efficacy estimates, it was associated with more adverse events and has limited direct clinical applicability. Treatment decisions should therefore weigh potential benefits against risks and safety considerations for each patient.

Egyptian Rheumatology and RehabilitationVol. 53(1)
Security Forces Hospital (SA), October 6 University (EG)
Spondyloarthritis Studies and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon